# Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

> **NCT05529355** · PHASE2 · UNKNOWN · sponsor: **Anhui Chest Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Envafolimab plus Endostar and S-1
- **DRUG:** Envafolimab plus Endostar
- **DRUG:** Envafolimab plus S-1

## Key facts

- **NCT ID:** NCT05529355
- **Lead sponsor:** Anhui Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-18
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529355, "Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05529355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*